Tag: rare disease gene therapy adverse event reporting process
2024 FDA Gene Therapy Safety Monitoring Requirements: Rare Disease Off-Target Risks, Long-Term Side Effects & Adverse Event Reporting Guidelines
October 2024 updated: Per FDA CBER, Tufts Center for the Study of Drug Development, and 2024 NIH data, 58% of rare disease gene therapy developers that meet 2024 safety monitoring rules get first-cycle FDA approval. This buying guide compares premium vs counterfeit unvetted regulatory guidance models to help you avoid $100k+ non-compliance fines and 6+